Akari Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKTX and other ETFs, options, and stocks.

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.

CEO

Abizer Gaslightwala

CEOAbizer Gaslightwala

Employees

Employees9

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

2004

Founded2004

Employees

Employees9

AKTX Key Statistics

Market cap

33.64M

Market cap33.64M

Price-Earnings ratio

-0.17

Price-Earnings ratio-0.17

Dividend yield

—

Dividend yield—

Average volume

23.91K

Average volume23.91K

High today

$1.19

High today$1.19

Low today

$1.16

Low today$1.16

Open price

$1.18

Open price$1.18

Volume

7.10K

Volume7.10K

52 Week high

$4.40

52 Week high$4.40

52 Week low

$0.85

52 Week low$0.85

Akari Therapeutics

Why Robinhood?

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Show more

AKTX Key Statistics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.